Global Breast Cancer Therapy Market 2018 Forecast to 2023: Increasing Investments on R&D is Driving the Market - ResearchAndMarkets.com

DUBLIN--()--The "Global Breast Cancer Therapy Market - Segmented by Therapy and Geography - Growth, Trends, and Forecast (2018 - 2023)" report has been added to ResearchAndMarkets.com's offering.

The global breast cancer therapy market is expected to register a CAGR of 8.5% during the forecast period 2018-2023. The high incidence rate of breast cancer is now becoming a concern, and several pharmaceutical companies are increasingly investing in research on breast cancer. Thus, the market is expected to grow.

Statistics say that around 50% of breast cancer cases and more than 58% of deaths occur in less developed countries. The National Cancer Institute has estimated that 246,660 cases of breast cancer were diagnosed in 2016. The high incidence and prevalence rate show that the breast cancer therapeutics market will boost over the forecast period.

Today, increasing number of countries are adopting early cancer detection programs, around the world. If these initiatives continue, the demand for breast cancer therapeutics is bound to increase, with most of the cases being detected in the early stages. Along with the other factors, such as high investments on R&D, and the advancements in cancer biology and pharmacology promoting drug development, are driving the market.

North America dominates the market for breast cancer therapy, due to the fact that the prevalence of breast cancer is on the rise in this region, along with an increase in R&D funding through public and private sectors. Asia-Pacific region is expected to grow at a significant pace, over the forecast period.

Market Dynamics

Drivers

  • High Incidence and Prevalence Rate of Breast Cancer Worldwide
  • Increasing Investments on R&D
  • Advancements in Cancer Biology & Pharmacology Promoting Drug Development

Restraints

  • Risk of Adverse Effects of Radiation Exposure
  • High Degree of Competition among Market Players

Key Developments in the Market

  • January 2018: U.S. FDA approved expanded use of AstraZeneca cancer drug, Lynparza.
  • November 2017: Bayer signed a partnership with cancer drug maker Loxo.

Key Topics Covered

1. Introduction

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)

7. Market Segmentation

8. Competitive Landscape

9. Key Players

  • AstraZeneca
  • Bayer
  • Beckman Coulter
  • Bristol Myer Squibb
  • Eisai
  • Merck & Co.
  • Novartis
  • Novocure
  • Pfizer
  • Roche

10. Future of the Market

For more information about this report visit https://www.researchandmarkets.com/research/v9grn8/global_breast?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Women's Health

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Women's Health